



NEWS RELEASE

For Immediate Release

Contact:

BioWa, Inc.
Masamichi Koike, Ph.D.
President and CEO
Phone: +1-609-580-7500

BIOWA APPOINTS NEW VICE PRESIDENT, CORPORATE DEVELOPMENT

Princeton, NJ, USA, July 29, 2009 – BioWa, Inc. has announced the appointment of Marc Silver to Vice President, Corporate Development. Mr. Silver will be responsible for continued business development of BioWa's POTELLIGENT[®] platform, and extending BioWa's business activities into related areas.

"We're energized by the prospect of Mr. Silver leading our business development initiatives" explained Dr. Masamichi Koike, President and CEO of BioWa, Inc. "He joins us at an important time in BioWa's growth cycle. His business development and strategic investment expertise will be particularly important as we seek to build upon our established collaborator base in the therapeutic antibody space."

Mr. Silver has over twenty years of strategic and transactional business development experience in the biopharmaceutical industry. He previously held senior management positions at Praecis Pharmaceuticals, Ardais Corp. and the American Type Culture Collection where his responsibilities included corporate partnership development, licensing, and intellectual property management. He has an extensive "deal sheet" including a number of significant development and commercialization transactions. Mr. Silver has also been involved in the founding, financing and initial development of life science companies including Aspect Medical Corp., Arris Pharmaceuticals, TargeTech Inc. and Envirogen Corp. He received an undergraduate degree in Biochemistry from Carnegie Mellon University and his Master's in Business from MIT's Sloan School of Management.

About POTELLIGENT[®] Technology

POTELLIGENT[®] Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT[®] Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT[®] Technology dramatically enhances ADCC activity of an antibody *in vitro*, and significantly increases potency and efficacy of the antibody *in vivo*. A number of POTELLIGENT[®] antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab[™] platform. AccretaMab[™] platform consists of POTELLIGENT[®] and COMPLEGENT[™] Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT[®] and COMPLEGENT[™] Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at www.biowa.com.

POTELLIGENT[®], COMPLEGENT[™], and AccretaMab[™] are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

###